RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.
about
Molecular Targeted Therapies of Aggressive Thyroid CancerThe Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyIntegrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomasParacrine regulation of pancreatic cancer cell invasion by peripheral nerves.EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cellsMedullary thyroid carcinoma: molecular signaling pathways and emerging therapiesNew therapies for dedifferentiated papillary thyroid cancerSelective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissuesIntracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein.HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.New agents in the treatment for malignancies of the salivary and thyroid glands.The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid CancerVandetanib for the treatment of thyroid cancer.RET TKI: potential role in thyroid cancers.Genetics and epigenetics of sporadic thyroid cancer.The RET oncogene in papillary thyroid carcinoma.Selective use of vandetanib in the treatment of thyroid cancer.Loss of sorting nexin 5 stabilizes internalized growth factor receptors to promote thyroid cancer progression.Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Personalization of targeted therapy in advanced thyroid cancer.Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.Angiotensin II-induced activation of c-Ret signaling is critical in ureteric bud branching morphogenesis.Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study.EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Targeted Therapy for Medullary Thyroid Cancer: A Review.
P2860
Q26774734-74E2D1A9-7913-4F77-8EA2-7F2F92C33EA2Q28073335-3F677602-9F58-4B4F-8B87-AD0216F49A10Q28475549-4E587E51-B17D-4C33-AAE9-72D6278F9462Q30433458-CF0640AE-1F19-4F2F-BC34-82AA03227899Q33688972-F61B478B-E0C9-4A32-97E7-4899D3AA9AF9Q34380617-27AA496E-E339-433F-94BE-7EFD1358A649Q35038893-93E9C73C-EA1F-487D-8300-6AB99C1AE07CQ35381593-53886D03-E5AB-42AE-BC9D-A4B4AEDC67A0Q35437491-84CE50BE-0D30-4FFF-8C58-80A98A729436Q35803941-465738C3-4116-4DFC-B738-C6D9C3E8971DQ35977327-16955FA1-550C-4898-8E9D-9C134DE8B395Q36562038-FEA138FF-B216-4D53-AB63-96805BCC85E1Q36729440-C520AEAF-F7AB-4C46-AD8D-628E5F209653Q37137859-A6FEA15A-FF1B-49F1-B68B-EAA154C611B8Q37351482-B1BB08E3-7FCD-4502-BE12-9868C09A6594Q37902072-A31BBB87-D41E-4A72-BAB6-7BB30ABB335EQ37967112-DCB3EEFC-4A18-4D4C-8EB1-F2C72A1546F9Q37979656-C8D3D1FB-01F6-4BA7-9269-2D690C82BE8CQ38128097-B090EA7E-BD03-49B9-AD7C-BC3184FE2EBFQ38366765-1CDCE026-1682-4025-B495-1F44F8EF3C47Q38546474-A577A9AA-2727-4783-9B80-BEB2680EB036Q38644201-A059EF4D-4B8D-4764-B57D-41539D0B0450Q38683133-F167DA62-AB87-4A41-B0C2-BBE757652524Q38960074-7843FABD-37C1-4ADF-8ECF-4D15B828D87DQ40922523-5F89FAD2-20F6-45A6-8F38-2417C483F98AQ41251561-EFC2677A-67A4-400F-B305-A066C7838471Q41981235-03CBB6D4-593B-491C-8693-BD5E3A987E13Q42910496-CA673A23-BA14-4AF2-941A-4EF345BBEE86Q45232514-132ABD26-32B8-4D2F-85DD-240CAAB91B3CQ47137989-A81F29BC-CF1A-4EA4-8D45-43D36E73E7F7Q47601932-BD3C9CB0-0432-4F1C-896D-E3F8D74A7482Q49328959-E4DF9A96-F294-4576-9911-DD4EF0129B58
P2860
RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
RET/PTC-induced cell growth is ...... ractions between RET and EGFR.
@ast
RET/PTC-induced cell growth is ...... ractions between RET and EGFR.
@en
type
label
RET/PTC-induced cell growth is ...... ractions between RET and EGFR.
@ast
RET/PTC-induced cell growth is ...... ractions between RET and EGFR.
@en
prefLabel
RET/PTC-induced cell growth is ...... ractions between RET and EGFR.
@ast
RET/PTC-induced cell growth is ...... ractions between RET and EGFR.
@en
P2093
P2860
P1433
P1476
RET/PTC-induced cell growth is ...... ractions between RET and EGFR.
@en
P2093
Doriano Fabbro
Heidi A Lane
Jacqueline E Baumgartner
James A Fagin
Jeffrey A Knauf
Michelle Croyle
Nagako Akeno
P2860
P304
P356
10.1158/0008-5472.CAN-08-0413
P407
P577
2008-06-01T00:00:00Z